SB 5B[™] Supports Diarrhoeal Illness and Immune Function





SB 5B[™] is an evidence-based probiotic yeast that provides targeted support for healthy immune function and diarrhoeal illness.

Saccharomyces cerevisiae ssp. boulardii (SB) is a beneficial probiotic yeast that helps to maintain gastrointestinal function and integrity by supporting a healthy gut microbial profile; increasing the production of secretory IgA (sIgA), short-chain fatty acids and the activity of brush border disaccharide digestive enzymes. SB has demonstrated clinical efficacy in relieving diarrhoea severity and duration due to various triggers in both children and adults and may be used to support symptoms of infectious, antibiotic-associated or traveller's diarrhoea. SB supports immune function with a predominant anti-inflammatory effect and also neutralises bacterial toxins along the gastrointestinal tract.^{1-4,13}

Key Features and Benefits:

- 5 Billion CFU of *Saccharomyces cerevisiae ssp. boulardii* per capsule
- Supports gastrointestinal immune function^{5,6}
- Assists in reducing the severity and duration of diarrhoea⁷⁻⁹
- Helps maintain healthy digestive function¹⁰
- Assists in the management of medically diagnosed Irritable Bowel Syndrome^{11,12}
- Aids in maintenance of general well being









Equiv.

250 mg 5 billion CFU*

Take one (1) capsule, one (1) to two (2) times daily, or as directed by your health professional.

AUST L 268232

*Colony Forming Units

Excipients: Cellulose, Silica, Magnesium Stearate, Calcium Hydrogen Phosphate.

WARNING: If symptoms persist consult your healthcare practitioner. Seek medical advice if diarrhoea persists for more than: 6 hours in infants under 6 months, 12 hours in children under 3 years; 24 hours in children aged 3-6 years and 48 hours in children over 6 years and adults.

REFERENCES

- Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 2007;23:679-692
- 1. Pothoulakis C. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther 2009;30:826–833. Ng S, Hart A, et al. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009;15:300–310.
- 4
- Vandenplas Y. Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part II: Yeasts. Clin Microbiol Infect 1999;5:389-395.
- 5. 6. , Surawicz C, et al. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA Elmer C
- 1996;275:870-876. 7.
- Kollaritsch H, Holst H, et al. Prevention of traveler's diarrhoea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Fortschr Med 1993;111:152-156.
- 8
- Szajewska H, Skorka A, et al. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007;25: 257–264. D'Souza A, Rajkumar C, et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324:1361. .Garcia V, De Lourdes M, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 10 2008;43:842-848.
- Maupas J, Champemont P, et al. Treatment of irritable bowel syndrome: double blind trial of Saccharomyces boulardii. Med Chir Dig 1983;12:77-79.
 Choi C, Jo S, et al. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011;45:679-683.
- 13. McFarland LV. Systematic review and meta-analysis of Saccromyces boulardii in adult patients. World J Gastroenterol 2010;16:2202.

Available from: **Integrated Nutraceuticals Limited** Room 604, 6/F., Seaview Commercial Building 21-24 Connaught Road West, Sheung Wan Hong Kong. (+852) 6799 4200 or visit www.inl.asia





